LIVZON PHARMA (01513) announced that its subsidiary, Zhuhai Livzon Monoclonal Antibody Biotechnology Co., Ltd., has received a Drug Clinical Trial Approval Notice (Notice No.: 2026LP03262) from the National Medical Products Administration.
The approval permits the clinical trial of the recombinant humanized anti-FXI bispecific antibody injection filed by Livzon Monoclonal Antibody for the indication of "prevention of venous thromboembolism after total knee arthroplasty."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments